On August 9, the National Health and Medical Commission issued the “Notice on Including Azvudine Tablets in the Novel Coronavirus Pneumonia Diagnosis and Treatment Program”. The notice mentioned that, according to the approval opinion of the State Food and Drug Administration on the conditional approval of azvudine tablets to increase the registration application for the treatment of new coronavirus pneumonia, in order to further improve the antiviral treatment plan for new coronavirus pneumonia, the drug was included in the research after research. “Diagnosis and Treatment Plan for Novel Coronavirus Pneumonia (Ninth Edition)”.
